- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03075228
Comparison of the Microbial Composition in Lean and Obese Subjects (DUPLO)
July 11, 2017 updated by: NIZO Food Research
DUPLO Study: Comparison of the Microbial Composition of the Upper Gastrointestinal Tract in Lean and Obese Subjects
Rationale: The microbial composition in the small intestine (SI) differs largely from the composition in feces.
Many physiological processes related to health, such as immunoregulation and metabolic programming, mainly take place in the SI.
Therefore, the SI, from a microbiota perspective, is as relevant as the large intestine.
There are indications that microbiota composition is different in lean and obese subjects, and is related to insulin resistance.
However, these indications are mainly based on the analysis of fecal samples.
Therefore, analysis of the microbiota composition in the more proximal part of the gastrointestinal (GI) tract may provide new insights into the microbial species that are involved or related to metabolic homeostasis at that location.
The IntelliCap® CR system offers a minimally invasive tool that is able to collect reliable samples in the SI, as was shown by NIZO in a clinical validation study.
The main aim of the current study is to explore and compare the upper GI microbiota composition in lean and obese subjects, in order to generate new leads for development of products that may target the upper GI microbiota community or specific species thereof, which may impact the maintenance of metabolic homeostasis.
This may provide new opportunities for the treatment, reduction or prevention of overweight and/or obesity or insulin resistance.
Study Overview
Study Type
Observational
Enrollment (Actual)
10
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ede, Netherlands, 6710 BA
- NIZO food research BV
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Ten (10) apparently healthy lean female subjects, as well as ten (10) apparently healthy obese female subjects, all aged 25-50y, will be recruited locally/regionally from the general population.
Description
Inclusion Criteria:
- Female;
- Age: 25-50y;
- Lean: BMI 19-23 kg/m2, waist circumference <80 cm, and fasting glucose <6.1 mmol/L; Obese: BMI 30-35 kg/m2, waist circumference >88 cm, and fasting glucose >=6.1 and <7.5 mmol/L;
- Healthy as assessed by the NIZO lifestyle and health questionnaire ("Verklaring leefgewoonten en gezondheid");
- Healthy as assessed by results of the pre-study safety laboratory tests (clinical chemistry: liver/kidney function etc);
- Regular and normal Dutch eating habits as assessed by the NIZO lifestyle and health questionnaire (3 main meals per day);
- Regular bowel movement (defecation on average once a day, at least 4 times/week).
Exclusion Criteria:
- Participation in any clinical trial with oral, intravenous or inhalatory administration of any substances during 90 days before study start;
History or presence of any clinically important disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study:
- type 1 or type 2 diabetes;
- gastrointestinal disease;
- bariatric surgery;
- cardiovascular disease, liver or renal failure or disease of the thyroid gland, cancer;
- infectious disease, history of chronic active inflammatory disorders or food allergy;
- Use of antibiotics during the one (1) year prior to study start; #
- Constipation/infrequent bowel movement (defecation <4 times per week);
- Having diarrhea within 3 months prior to the study start (at least 3 loose stools per day);
- Use of laxatives, fiber supplements (e.g. lactulose, inulin), glucose lowering drugs, insulin, anti-obesity drugs, immunosuppressive drugs (e.g. systemic corticosteroids, cyclosporine, azathioprine, antibodies) during the three (3) months prior to study start;
- Use of temporary or irregular medication for diabetes, dyslipidemia or hypertension;
- Use of any prescribed or non-prescribed medication (other than paracetamol) including antacids, H2 receptor antagonists, proton pump inhibitors, analgesics, herbal remedies or anti-inflammatory drugs (e.g. NSAIDs) during the three (3) weeks prior to study start;
- Use of probiotics or prebiotics during the three (3) months prior to study start;
- Mental status that is incompatible with the proper conduct of the study;
- Presence of swallowing or passage disorder;
- Carrying a pacemaker or any other (implanted) medical electronic device;
- Scheduled for an MRI scan during the study period;
- Not willing to have an X-ray if the capsule is not recovered from the faeces;
- Alcohol consumption > 15 units/week and >3/day. In case of less alcohol consumption: not willing to stop during the study;
- Drug abuse, and not willing/able to stop this during the study;
- Heavy exercise or sports training > 10 hours/week;
- Smoking;
- Active or recent participation in a weight loss program including weight change (increase or loss) of >3 kg during the last three (3) months;
- Reported unexplained weight loss or weight gain of > 5 kg in the year prior to pre-study screening;
- Reported slimming or medically prescribed diet;
- Reported special diets;
- Pregnant or planning to become pregnant during the study, breastfeeding ;
- Postmenopausal women on unstable hormone replacement therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Lean subjects
Lean is defined as having a BMI of 19-23 kg/m2, waist circumference <80 cm and fasting glucose levels <6.1 mmol/L.
|
Sampling of the small intestine using a samling capsule.
|
Obese subjects
Obese is defined as having a BMI of 30-35 kg/m2, waist circumference >88 cm and fasting glucose levels >=6.1 and <7.5 mmol/L
|
Sampling of the small intestine using a samling capsule.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Microbiota composition
Time Frame: 3 days after consuming a fully controlled western style diet
|
Relative abundance of microbiota species (% of total) in the small intestine in lean vs obese subjects
|
3 days after consuming a fully controlled western style diet
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total bacterial count
Time Frame: 3 days after consuming a fully controlled western style diet
|
Total bacterial count measured by qPCR in the small intestinal samples in lean vs obese subjects
|
3 days after consuming a fully controlled western style diet
|
Cytokine levels
Time Frame: 3 days after consuming a fully controlled western style diet
|
Cytokines levels in blood in relation to microbiota composition in lean vs obese subjects
|
3 days after consuming a fully controlled western style diet
|
Metabolic markers
Time Frame: 3 days after consuming a fully controlled western style diet
|
Glucose, insulin and cholesterol levels in blood in relation to microbiota composition in lean vs obese subjects
|
3 days after consuming a fully controlled western style diet
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Els van Hoffen, PhD, NIZO food research BV
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 25, 2017
Primary Completion (Actual)
July 4, 2017
Study Completion (Actual)
July 4, 2017
Study Registration Dates
First Submitted
March 6, 2017
First Submitted That Met QC Criteria
March 8, 2017
First Posted (Actual)
March 9, 2017
Study Record Updates
Last Update Posted (Actual)
July 14, 2017
Last Update Submitted That Met QC Criteria
July 11, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- NL 59327.081.16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on IntelliCap
-
NIZO Food ResearchWageningen UniversityCompletedMicrobiota Composition in the Human Small IntestineNetherlands
-
AstraZenecaCompletedPharmacokinetic Profile | Plasma ConcentrationUnited Kingdom